Online citations, reference lists, and bibliographies.

Development And Evaluation Of Rivastigmine Loaded Chitosan Nanoparticles For Brain Targeting.

M. Fazil, Shadab Md, S. Haque, M. Nireekshan Kumar, S. Baboota, J. Sahni, J. Ali
Published 2012 · Chemistry, Medicine
Referenced 1 time by Citationsy Users

Cite This
Download PDF
Analyze on Scholarcy
Share
The rivastigmine (RHT) loaded chitosan nanoparticles (CS-RHT NPs) were prepared by ionic gelation method to improve the bioavailability and enhance the uptake of RHT to the brain via intranasal (i.n.) delivery. CS-RHT NPs were characterized for particles size, particle size distribution (PDI), encapsulation efficiency, zeta potential and in vitro release study. Nose-to-brain delivery of placebo nanoparticles (CS-NPs) was investigated by confocal laser scanning microscopy technique using rhodamine-123 as a marker. The brain/blood ratio of RHT for different formulations were 0.235, 0.790 and 1.712 of RHT (i.v.), RHT (i.n.), and CS-RHT NPs (i.n.) respectively at 30 min are indicative of direct nose to brain transport bypassing the BBB. The brain concentration achieved from i.n. administration of CS-NPs (966 ± 20.66 ng ml(-1); t(max) 60 min) was significantly higher than those achieved after i.v. administration of RHT sol (387 ± 29.51 ngml(-1); t(max) 30 min), and i.n. administration of RHT solution (508.66 ± 22.50 ng ml(-1); t(max) 60 min). The higher drug transport efficiency (355 ± 13.52%) and direct transport percentage (71.80 ± 6.71%) were found with CS-RHT NPs as compared to other formulation. These results suggest that CS-RHT NPs have better brain targeting efficiency and are a promising approach for i.n. delivery of RHT for the treatment and prevention of Alzheimer's disease (AD).
This paper references
10.1016/j.ejpb.2010.07.007
Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies.
Shrinidh A Joshi (2010)
10.22037/IJPR.2010.845
HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF RIVASTIG¬MINE IN HUMAN PLASMA FOR APPLICATION IN PHARMACOKINETIC STUDIES
H. Amini (2010)
10.1016/S0142-9612(02)00071-6
Synthesis and characterization of chitosan-poly(acrylic acid) nanoparticles.
Y. Hu (2002)
10.1016/S0378-5173(99)00030-7
Effect of chitosan on epithelial permeability and structure.
V. Dodane (1999)
10.1016/S1359-0286(02)00117-1
Biodegradable nanoparticles for drug delivery and targeting
M. Hans (2002)
10.1016/0168-3659(87)90035-6
A simple equation for description of solute release II. Fickian and anomalous release from swellable devices
P. L. Ritger (1987)
10.4314/TJPR.V5I1.14634
Nanoparticles - A Review
V. Mohanraj (2007)
10.1016/S0168-3659(97)00105-3
Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats.
R. Löbenberg (1998)
10.1016/J.IJPHARM.2005.03.027
Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor.
Y. Aktaş (2005)
10.1016/J.IJPHARM.2005.01.042
Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate.
Yan Wu (2005)
10.3109/10611860903386938
Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats
S. Khan (2010)
10.1016/j.nano.2009.04.001
Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine.
B. Wilson (2010)
10.1081/DDC-120001481
Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier
P. Lockman (2002)
10.1016/J.EJPB.2004.03.010
In vitro permeation studies comparing bovine nasal mucosa, porcine cornea and artificial membrane: androstenedione in microemulsions and their components.
Telse Richter (2004)
10.1016/j.jconrel.2010.11.033
Neurotherapeutic applications of nanoparticles in Alzheimer's disease.
J. Sahni (2011)
10.1002/JPS.10143
Preparation, characterization, and drug release behaviors of drug nimodipine‐loaded poly(ε‐caprolactone)‐poly(ethylene oxide)‐poly(ε‐caprolactone) amphiphilic triblock copolymer micelles
Haixiong Ge (2002)
10.1016/J.JCONREL.2007.05.022
Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123.
G. Tosi (2007)
10.1016/J.CARBPOL.2010.02.026
Bioadhesive chitosan nanoparticles: Preparation and characterization
Anitha R. Dudhani (2010)
10.1016/J.IJPHARM.2004.01.039
Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain.
Q. Zhang (2004)
10.1016/j.ejpb.2008.07.005
Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting.
Xiaomei Wang (2008)
10.1016/J.CARBPOL.2007.11.007
Chitosan nanoparticles loaded with dorzolamide and pramipexole
Sofia A. Papadimitriou (2008)
10.1016/J.EJPB.2007.09.009
Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation.
S. Motwani (2008)
10.3109/10611860903483396
Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids viruses
Abeer M. Al-Ghananeem (2010)
10.1016/j.ijpharm.2008.03.029
Intranasal nanoemulsion based brain targeting drug delivery system of risperidone.
M. Kumar (2008)
10.1016/S0168-3659(01)00379-0
Investigation on a novel core-coated microspheres protein delivery system.
S. Zhou (2001)
10.1016/0168-3659(95)00146-8
The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro
G. Borchard (1996)
10.1016/j.nano.2009.04.007
Preparation and characterization of insulin nanoparticles using chitosan and Arabic gum with ionic gelation method.
M. R. Avadi (2010)
10.1016/S0169-409X(00)00118-6
Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future.
R. Mueller (2001)
10.1189/JLB.0904541
Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration.
C. Porporatto (2005)
10.1016/j.ijpharm.2007.11.052
Preparation, characterization and antibacterial activities of chitosan, N-trimethyl chitosan (TMC) and N-diethylmethyl chitosan (DEMC) nanoparticles loaded with insulin using both the ionotropic gelation and polyelectrolyte complexation methods.
A. Sadeghi (2008)
10.1016/j.coph.2009.06.012
Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin.
B. Ray (2009)
10.1016/j.nano.2009.02.005
Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution.
A. V. Vergoni (2009)
10.1016/j.colsurfb.2011.09.042
Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique.
W. Fan (2012)
10.1023/A:1012128907225
Chitosan and Chitosan/Ethylene Oxide-Propylene Oxide Block Copolymer Nanoparticles as Novel Carriers for Proteins and Vaccines
P. Calvo (2004)
10.1016/S0014-2999(99)00741-4
Inhibitory effects of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats.
T. Kosasa (1999)
10.1016/S0168-3659(01)00486-2
Design of biodegradable particles for protein delivery.
A. Vila (2002)
Drug delivery to the central nervous system: a review.
A. Misra (2003)



This paper is referenced by
10.1021/ACS.MOLPHARMACEUT.6B00586
Brain Targeting of Temozolomide via the Intranasal Route Using Lipid-Based Nanoparticles: Brain Pharmacokinetic and Scintigraphic Analyses.
Anam Khan (2016)
10.1007/978-3-030-30930-5_4
Nanobiotechnology in Neurodegenerative Diseases
Josef Jampílek (2019)
10.1088/0957-4484/27/43/435101
Design Expert(®) supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson's disease.
S. Kumar (2016)
10.1016/B978-0-12-803796-6.00006-X
Challenges of the Nose-to-Brain Route
Emine Şekerdağ (2017)
10.1002/9781118788523
Blood-Brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs
Li Di (2015)
10.1007/978-3-319-63633-7_10
CNS Drug Delivery for Diseases Eradication: An Overview
Anil Kumar Kalvala (2017)
10.1590/0104-1428.08118
Design of chitosan-alginate core-shell nanoparticules loaded with anacardic acid and cardol for drug delivery
João Campos Paiva Filho (2019)
10.3390/medicines5030103
Oleic Acid Nanovesicles of Minoxidil for Enhanced Follicular Delivery
Pawan Kumar (2018)
10.2174/1570163815666180418144019
Biopharmaceutical Potential of Selegiline Loaded Chitosan Nanoparticles in the Management of Parkinson's Disease.
Rajalakshmi Rukmangathen (2018)
10.1007/s11095-017-2279-z
Formulation and In-vivo Pharmacokinetic Consideration of Intranasal Microemulsion and Mucoadhesive Microemulsion of Rivastigmine for Brain Targeting
B. Shah (2017)
10.1002/adma.201801362
Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases.
Denzil Furtado (2018)
10.1002/jps.24557
Intranasal Piperine-Loaded Chitosan Nanoparticles as Brain-Targeted Therapy in Alzheimer's Disease: Optimization, Biological Efficacy, and Potential Toxicity.
Y. Elnaggar (2015)
10.1016/j.resp.2012.12.005
Modeling of release position and ventilation effects on olfactory aerosol drug delivery
Xiuhua Si (2013)
10.1517/17425247.2013.762354
Drug targeting to brain: a systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB
Kalpana Nagpal (2013)
10.1016/j.apsb.2013.12.009
Comparative pharmacokinetics of tetramethylpyrazine phosphate in rat plasma and extracellular fluid of brain after intranasal, intragastric and intravenous administration
Dongmei Meng (2014)
10.1002/9783527682157.CH04
Nanoparticles: Important Tools to Overcome the Blood–Brain Barrier and Their Use for Brain Imaging
Ruirui Qiao (2015)
10.1016/j.ijbiomac.2015.07.041
Brain delivery of buspirone hydrochloride chitosan nanoparticles for the treatment of general anxiety disorder.
N Bari (2015)
10.1007/978-3-319-41926-8_3
Chitosan Based Nanomaterials and Its Applications
Saurabh Bhatia (2016)
PRELIMINARY STUDIES ON BRAIN TARGETING OF INTRANASAL ATOMOXETINE LIPOSOMES
Amruta V. Vaidya (2016)
10.1016/B978-0-12-803796-6.00012-5
Chapter 12 – Alzheimer
Qizhi Zhang (2017)
10.1016/j.jpsychires.2013.10.011
Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression.
S. Haque (2014)
10.3109/03639045.2014.991400
Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting
Omidreza Jafarieh (2015)
10.1517/17425247.2015.1065812
Intranasal delivery: circumventing the iron curtain to treat neurological disorders
Yongjun Jiang (2015)
10.2147/IJN.S87148
Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease
Bruno Fonseca-Santos (2015)
10.1021/acs.molpharmaceut.5b00402
Brain Targeting of a Water Insoluble Antipsychotic Drug Haloperidol via the Intranasal Route Using PAMAM Dendrimer.
Y. K. Katare (2015)
10.3389/fnagi.2018.00284
Phyto-Therapeutic and Nanomedicinal Approaches to Cure Alzheimer’s Disease: Present Status and Future Opportunities
M. Ovais (2018)
10.1080/10717544.2017.1377315
Brain targeted oral delivery of doxycycline hydrochloride encapsulated Tween 80 coated chitosan nanoparticles against ketamine induced psychosis: behavioral, biochemical, neurochemical and histological alterations in mice
M. Yadav (2017)
10.1007/s11095-013-1122-4
Targeted Delivery of Nano-Therapeutics for Major Disorders of the Central Nervous System
Huile Gao (2013)
10.1016/J.BFOPCU.2015.10.001
Nanostructured lipid carrier system for topical delivery of terbinafine hydrochloride
Bharti Gaba (2015)
10.1016/j.ijpharm.2020.119148
Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease.
Subrat Kumar Bhattamisra (2020)
10.3390/cancers5031020
Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?
M. van Woensel (2013)
10.1016/j.jconrel.2015.03.024
Nanoparticle-mediated growth factor delivery systems: A new way to treat Alzheimer's disease.
Marc-Antoine Lauzon (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar